Search Results - "Negrier C"

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq^® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A.

Authors: Dargaud, Y. Negrier, C. Rusen, L. et al.

Source: Haemophilia. Jul2018, Vol. 24 Issue 4, p619-627. 9p. 1 Diagram, 2 Charts, 6 Graphs.

Recombinant long-acting glyco PEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.

Authors: Negrier, C. Young, G. Abdul Karim, F. et al.

Source: Haemophilia. Jul2016, Vol. 22 Issue 4, p507-513. 7p.

Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.

Authors: Berntorp, E. Negrier, C. Gozzi, P. et al.

Source: Haemophilia. May2016, Vol. 22 Issue 3, p389-396. 8p.

The first recombinant FVIII produced in human cells - an update on its clinical development programme.

Authors: Valentino, L. A. Negrier, C. Kohla, G. et al.

Source: Haemophilia. Jan2014 Supplement, Vol. 20, p1-9. 9p.

The benefits of exercise for patients with haemophilia and recommendations for safe and effective physical activity.

Authors: Negrier, C. Seuser, A. Forsyth, A. et al.

Source: Haemophilia. Jul2013, Vol. 19 Issue 4, p487-498. 12p. 3 Charts.

Optimizing on-demand treatment with NovoSeven^® room temperature stable.

Authors: NEGRIER, C.¹ claude.negrier@chu-lyon.fr

Source: Haemophilia. May2010 Supplement 3, Vol. 16, p35-40. 6p.

Thrombin generation testing in haemophilia comprehensive care centres.

Authors: DARGAUD, Y. NEGRIER, C.

Source: Haemophilia. Mar2010, Vol. 16 Issue 2, p223-230. 8p. 2 Graphs.

European curriculum for thrombosis and haemostasis.

Authors: ASTERMARK, J. NEGRIER, C. HERMANS, C. et al.

Source: Haemophilia. Jan2009, Vol. 15 Issue 1, p337-344. 8p.

Basic aspects of bypassing agents.

Authors: NEGRIER, C. DARGAUD, Y. BORDET, J. C.

Source: Haemophilia. Dec2006 Supplement 3, Vol. 12, p48-53. 6p.

Coagulation factor concentrates: past, present, and future.

Authors: Key NS Negrier C

Source: Lancet. 8/4/2007, Vol. 370 Issue 9585, p439-448. 10p.

The association of haemophilic arthropathy with Health-Related Quality of Life: a post hoc analysis.

Authors: Fischer, K. Kleijn, P. Negrier, C. et al.

Source: Haemophilia. Nov2016, Vol. 22 Issue 6, p833-840. 8p. 4 Charts, 1 Graph.

New developments in laboratory diagnosis and monitoring.

Authors: KITCHEN, S. HAYWARD, C. NEGRIER, C. et al.

Source: Haemophilia. Jul2010 Supplement 5, Vol. 16, p61-66. 6p.

The pharmacokinetics of coagulation factors.

Authors: Lee, M. Morfini, M. Negrier, C. et al.

Source: Haemophilia. May2006 Supplement, Vol. 12, p1-7. 7p.

Haemophilia and thrombophilia: an unexpected association!

Authors: Dargaud, Y. Meunier, S. Negrier, C.

Source: Haemophilia. Jul2004, Vol. 10 Issue 4, p319-326. 8p.

Pharmacokinetics of a novel extended half-life glyco PEGylated factor IX, nonacog beta pegol (N9- GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

Authors: Tiede, A. Abdul-Karim, F. Carcao, M. et al.

Source: Haemophilia. Jul2017, Vol. 23 Issue 4, p547-555. 9p. 3 Charts, 4 Graphs.

Molecular cytogenetic characterization of five F8 complex rearrangements: utility for haemophilia A genetic counselling.

Authors: Jourdy, Y. Chatron, N. Fretigny, M. et al.

Source: Haemophilia. Jul2017, Vol. 23 Issue 4, pe316-e323. 8p. 1 Diagram, 2 Charts.

Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.

Authors: Iorio, A. Iserman, E. Blanchette, V. et al.

Source: Haemophilia. May2017, Vol. 23, pe170-e179. 10p.

Characterization of five associations of F8 missense mutations containing FVIII B domain mutations.

Authors: Jourdy, Y. Nougier, C. Roualdes, O. et al.

Source: Haemophilia. Jul2016, Vol. 22 Issue 4, p583-589. 7p.

In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.

Authors: Enjolras, N. Perot, E. Le Quellec, S. et al.

Source: Haemophilia. Jul2015, Vol. 21 Issue 4, pe317-e321. 5p. 2 Graphs.

Usefulness of an in vitro cellular expression model for haemophilia A carrier diagnosis: illustration with five novel mutations in the F8 gene in women with isolated factor VIII:C deficiency.

Authors: Roualdes, O. Nougier, C. Fretigny, M. et al.

Source: Haemophilia. May2015, Vol. 21 Issue 3, pe202-e209. 8p. 2 Charts, 1 Graph.